



東瑞製藥（控股）有限公司
Dawnrays Pharmaceutical (Holdings) Limited

(Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立的有限公司)

Suites 3212-13, Shell Tower, Times Square, 1 Matheson Street, Hong Kong

Tel: 852-2111 9708 Fax: 852-2111 9870

FOR IMMEDIATE RELEASE

PRESS RELEASE

Attn: Business Editor

Dawnrays Pharmaceutical (Holdings) Limited

Announced Annual Results For The Year Ended 31 December 2010

Net profit after tax jumped 41.0% to RMB 166.84 million
A final dividend of HK\$ 0.078 per share was declared

(Hong Kong, 14 March 2011) **Dawnrays Pharmaceutical (Holdings) Limited** (“Dawnrays Pharma” or the “Group”, The Stock Exchange of Hong Kong Stock Code: 2348) announced annual results for the year ended 31 December 2010. Turnover amounted to approximately RMB 1,286,683,000 (2009: RMB 1,082,110,000), representing an increase of 18.9% compared with the corresponding period of last year. Profit attributable to owners of the parent amounted to approximately RMB 166,840,000 (2009: RMB 118,388,000), representing an increase of 40.9% when compared to that of last year. Basic earnings per share was approximately RMB 0.2104 (2009: RMB 0.1513). The Board recommends the payment of a final dividend of HK\$ 0.078 per share for the year ended 31 December 2010 (2009: HK\$ 0.05). Taking into consideration the interim dividend of HK\$ 0.02 per share, the total annual dividend distributed for the year is HK\$ 0.098 per share (2009: HK\$ 0.068). The dividend payout ratio is approximately 39.7%.

Ms. Li Kei Ling, Chairman of Dawnrays Pharma, said, “2011 is the year for China to achieve new medical reforms. A series of policies were introduced by the end of 2010 to push forward the accomplishment of the goals of medical reform phase by phase, and such policies will continue in 2011. Implementation of the new edition of GMP will bring a new round of consolidations and restructures and accelerate the process of the integration of pharmaceutical industry. The Government will support innovative R & D projects of key domains with various measures. These policy factors are expected to have great impact on the pharmaceutical economy of China. Directors believe that the Group will continuously pursue flexible future development directions. Attention to cost, speed to market, and decision-making of capital

allocations can still reap rewards and enhance our R & D productivity. In 2011, the Board will consider the agenda of R & D, new product marketing plans, and optimization of resource allocations as first priorities. In this way, we can create value and maintain sustainability for all the shareholders. ”

The Group gave a review to its overall performance in 2010. With respect to sales, the intermediates and bulk medicines and solid-dosage-forms (mainly system specific medicines) businesses have been the main driver for revenue growth. In particular, since the Group has been enhancing the market penetration actions in the field of cardiovascular system specific medicines and expanding the scale effect. Therefore, the market share was further expanded as well as optimized the Group’s product portfolio. The main products such as anti-infective medicines “Xianshu” (先舒)(Cefoperazone Sodium and Sulbactam Sodium for Injection), “Xiankang” (先康)(Cefepime Hydrochloride for injection), and system specific medicines including “Anneizhen” (安內真)(Amlodipine Besylate Tablets), “Anneixi” (安內喜)(Losartan Potassium and Hydrochlorothiazide Tablets), “Anneiqiang” (安內強)(Telmisartan Tablets), “Xikewei” (西可韋)(Cetirizine Hydrochloride Tablets), “Leiyide” (雷易德)(Entecavir Dispersible Tablets),etc. continued positive growth in sales.

On the research and development front, in 2010, the Group obtained 3 production permits for Lansoprazole Tablets (蘭索拉唑片), Entecavir Bulk Medicines and Dispersible Tablets (恩替卡韋原料及分散片) from the State Food and Drug Administration, received 28 supplemental production permits for 16 products, 82 re-registered production permits for 37 products and 1 clinical permit. And 4 new products had been applied for production permits (including 3 antibiotic products and 1 system specific medicine for cardiovascular system). In addition, 5 products were under clinical trials.

Looking ahead, the management of Dawnrays Pharma will proactively react according to the medical reform, continue to develop by following the direction of “professionalism, excellence, specialization, and innovation”, while further reinforcing and expanding the market share of the Group’s products in the fields of anti-infection, cardiovascular, anti-virus and allergy; speeding up the construction of solid-dosage-form workshop for system specific medicines, so as to get prepared for the enhancement in production capacity of system specific medicines, steadily push forward the R & D process of new products and further improve the production quality of the products in 2011.

About Dawnrays Pharmaceutical (Holdings) Limited

Dawnrays Pharmaceutical (Holdings) Limited (Stock Code: 2348) is a leading vertically integrated pharmaceutical group in China with core competencies in the manufacturing of cephalosporins and system specific medicines. Founded in 1995, the Group was listed on the Main Board of the Stock Exchange of Hong Kong in July 2003.

Dawnrays Pharma is among one of the earliest pharmaceutical companies in China granted the GMP certification. The Group is principally engaged in the development, manufacturing and sales of cephalosporins and various system specific medicines. Dawnrays Pharma is one of the few comprehensive vertically integrated 3rd generation cephalosporin manufacturers in China, adopting distinctive production process from pharmaceutical intermediates to bulk medicines and pharmaceutical preparations. Its system specific medicines cover a wide range of therapeutic areas for cardiovascular system, anti-viral, anti-allergic, digestive system, urinary system and endocrine system, etc. The dosage forms of the Group's pharmaceutical preparations include powder for injections, tablets, capsules and granules, etc.

— End —

This press release is issued by Dawnrays Pharmaceutical (Holdings) Limited.
For further enquiries, please contact:

Vanessa Yeung / Michelle Li
Corporate Communications
Tel : 852-2111 9708
Fax : 852-2111 9870
Email : ir@dawnrays.com.hk

Financial Highlights

Dawnrays Pharmaceutical (Holdings) Limited

Announced Annual Results For The Year Ended 31 December 2010

For the year ended 31 December

	2010 (Audited) RMB '000	2009 (Audited) RMB '000
Revenue	1,286,683	1,082,110
Cost of sales	<u>(910,526)</u>	<u>(754,058)</u>
Gross profit	376,157	328,052
Other income and gains	9,145	4,595
Selling and distribution costs	(95,673)	(101,206)
Administrative expenses	(48,884)	(47,575)
Other expenses	(31,317)	(32,008)
Finance costs	<u>(549)</u>	<u>(395)</u>
Profit before tax	208,879	151,463
Income tax expense	<u>(42,041)</u>	<u>(33,119)</u>
Profit for the year	<u>166,838</u>	<u>118,344</u>
Attributable to :		
Owners of the parent	166,840	118,388
Non-controlling interest	<u>(2)</u>	<u>(44)</u>
	<u>166,838</u>	<u>118,344</u>
Dividends :		
Interim	13,726	12,452
Proposed final	<u>52,472</u>	<u>34,769</u>
Earnings per share attributable to ordinary equity holders of the parent		
– basic, for profit for the year	<u>RMB 0.2104</u>	<u>RMB 0.1513</u>
– diluted, for profit for the year	<u>RMB 0.2093</u>	<u>RMB 0.1506</u>